BUDGETARY IMPACT ANALYSIS OF LEVETIRACETAM USE FOR FOCAL EPILEPSY PATIENTS' TREATMENT WITH OR WITHOUT SECONDARY GENERALIZATION FROM THE BRAZILIAN PUBLIC HEALTH SYSTEM PERSPECTIVE
Author(s)
Carmo E1, Nita ME2, Motta R1, Lima F1
1UCB Biopharma, São Paulo, Brazil, 2IECS, HAOC, and FIPE, Sao Paulo, Brazil
Presentation Documents
OBJECTIVES: The Brazilian Clinical Protocol and Therapeutic Guideline (PCDT) for epilepsy treatment includes twelve different anti-epileptic drugs (AEDs). Currently, levetiracetam (LEV) is not an option on the PCDT. Our objective was to evaluate the potential budgetary impact of LEV use as monotherapy treatment of focal seizures (partial-onset) with or without second generalization in patients over 16 years old in case of adoption by the National Public Health System. METHODS: A budget impact model was developed covering a 5-year period. Patient population and yearly incidence rates applied in the model were extracted from the Brazilian Unified Health System (SUS) database, the DATASUS. Two hypothetical scenarios were compared based on expert opinion and the current clinical guidelines: levetiracetam monotherapy versus valproic acid monotherapy, both as first line treatments. Subsequent treatment lines were the same in both scenarios: 2nd line-carbamazepine monotherapy; 3rd line-topiramate monotherapy; 4th line-lamotrigine adjuvant; 5th line-gabapentin adjuvant; 6th line-surgery. It was assumed that levetiracetam would fully replace valproic acid monotherapy. Yearly drug acquisition of all AEDs and surgery costs were considered in local currency; Reais. RESULTS: CONCLUSIONS: The introduction of LEV as a new therapeutic option for epilepsy patients with focal seizures with or without second generalization is anticipated to be associated with cost savings of R$5,968,021 in year 5 and cumulative cost savings of R$24.348.756 over 5 years for the Brazilian public health system. UCB-Pharma sponsored
Conference/Value in Health Info
2016-05, ISPOR 2016, Washington DC, USA
Value in Health, Vol. 19, No. 3 (May 2016)
Code
PND14
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Neurological Disorders